Quit Smoking Journey

Quitting Methods Compared: The Real Question Isn't Which Method

Cold turkey, NRT, varenicline, e-cigarettes, combination — the differences between methods are smaller than the differences between people on the same method. What that actually means.

Updated: By Editorial Team

There are roughly six quit-smoking methods you’ll encounter: cold turkey, nicotine replacement therapy (patches, gum, lozenges, inhalers, sprays), varenicline (Champix/Chantix), bupropion, e-cigarettes, and cytisine. Hundreds of articles compare them. Most of those comparisons miss the actual finding from the cessation literature.

The variance in success rates between methods is small. The variance within each method, between different individuals, is much larger.

A patch can take you from a 3% to a 15% chance at 6-month abstinence. Whether you have one named friend who’ll text you on day 3 can shift you another 10 percentage points on top of that. Whether you have untreated depression can cancel out everything else.

This means the most heavily marketed question — which method should I pick? — is mostly the wrong question. The right questions are downstream of method choice.

The wrong question

Here is what the meta-analyses converge on, expressed as 6-month continuous abstinence rates:

  • Unaided (cold turkey, no support): ~3–5%
  • Single-form NRT alone: ~7–11%
  • Combination NRT (patch + faster-acting form): ~15–18%
  • Varenicline alone: ~18–22%
  • Combination NRT + behavioral support: ~20–28%
  • Varenicline + behavioral support: ~25–30%

Sources: Cahill et al., Cochrane, 2013 for pharmacotherapy meta-analysis; Stead et al., Cochrane, 2012 for combination NRT; Hartmann-Boyce et al., Cochrane, 2018 for behavioral support effects.

Notice the spread. The best evidence-based method roughly sextuples your odds versus unaided cold turkey. That’s significant. But notice also: even the best method only gets you to about 30% at 6 months. Seventy percent of people on the best-supported regimen still relapse within half a year.

What predicts being in the 30% rather than the 70%, given the same method? The boring answers, mostly:

  • Prior quit attempts. People who’ve quit before are more likely to succeed this time. The Ontario Tobacco Survey followed 1,277 smokers and found a median of 30 quit attempts before sustained success (Chaiton et al., BMJ Open, 2016). This isn’t failure compounding — each attempt teaches something specific about your failure modes.
  • Current mental health. Active depression roughly doubles relapse risk, regardless of method (Hitsman et al., Nicotine & Tobacco Research, 2013).
  • A single named accountability person. Whether you have one specific human who knows your quit date and will check in matters more in the data than most pharmacological choices.
  • Your trigger context density. Working in a smoking-heavy environment, living with another smoker, having a daily routine that includes 5+ smoking-paired moments — these depress success rates across all methods.
  • Sleep quality in the first month. Sleep disruption peaks around days 3–10 and tracks with relapse risk. People who manage sleep through the first month do better.

If you’ve optimized none of these and you spend hours debating cold turkey vs NRT, you’re optimizing the wrong layer.

What each method actually does

Cold turkey. Stop smoking on a chosen date, no pharmacological support. The label is misleading — best evidence is not “decide right now and stop”, but “set a quit date 1–2 weeks ahead, prepare, then stop abruptly.” Lindson-Hawley’s 2016 trial of 697 participants found abrupt quitting outperformed gradual reduction (22% vs 15.5% at 4 weeks), but both groups had significant pre-quit preparation (Lindson-Hawley et al., Annals of Internal Medicine, 2016). The “just decide and stop” framing doesn’t match the data.

Nicotine replacement therapy. Delivers nicotine without combustion products, blunting withdrawal. Most heavy smokers are underdosed on standard regimens — a 21mg patch covers about a pack-a-day equivalent, and people smoking 30+ cigarettes daily often need 21mg + an additional 4mg gum or lozenge schedule. Single-form NRT is undertreatment for many users. (See our NRT product reviews for dosing detail.)

Varenicline. Partial agonist at nicotinic receptors. Both blunts withdrawal and reduces the rewarding effect of cigarettes if you do smoke. Highest single-pharmacotherapy success rate. Side effects (nausea, vivid dreams) are real but mostly tolerable. Earlier concerns about psychiatric side effects were largely resolved by the 2016 EAGLES trial which found no excess psychiatric events vs placebo or other cessation aids (Anthenelli et al., The Lancet, 2016).

Bupropion. Antidepressant repurposed for cessation. Roughly comparable to single-form NRT in efficacy. Useful if you also have depression — one drug, two indications. Mostly second-line otherwise.

E-cigarettes. Hajek’s 2019 NEJM trial found e-cigarettes roughly twice as effective as NRT for cessation in motivated quitters with face-to-face support (Hajek et al., NEJM, 2019). The finding remains controversial because of long-term safety uncertainty and concerns about dual-use, but the cessation efficacy data is real. Public health bodies disagree on whether to recommend them, with the UK NHS being notably more permissive than U.S. agencies.

Cytisine. Plant alkaloid with a similar mechanism to varenicline. A 2014 NEJM trial in New Zealand found cytisine outperformed NRT (40% vs 31% 1-month abstinence) (Walker et al., NEJM, 2014). It’s been used in Eastern Europe for decades. Most U.S. and Western European markets still don’t sell it. This is a regulatory artifact, not a scientific one.

Why combination beats solo

The empirical default for quit success isn’t any single method. It’s combination.

The strongest combination supported by trials:

  • Varenicline + behavioral counseling: highest tested 6-month abstinence rates in routine clinical settings (~30%).
  • Combination NRT (long-acting patch + short-acting gum/lozenge) + behavioral support: comparable to varenicline-based protocols, with fewer side effects.
  • Either pharmacotherapy + a quit-tracking tool with structured craving log: modest additional effect, well-established in Cochrane reviews (Whittaker et al., 2019).

The reason combinations work isn’t surprising. Different mechanisms address different parts of the failure mode. NRT addresses nicotine withdrawal. Behavioral support addresses trigger conditioning. Tracking tools address the maintenance window.

What still doesn’t work, despite being heavily marketed: hypnosis, acupuncture, “natural” herbal cessation aids, and most “personalized” quit plans that promise to match you to your “type.” The Cochrane reviews on these are uniformly unimpressive.

The contrarian thesis: the best method might be the one you’ve already failed at

Here is a finding that surprises most people: prior failed quit attempts are positively correlated with future quit success, particularly when the future attempt uses the same method and adjusts the failure mode.

The reason is mechanistic. Each failed attempt teaches you something specific about your failure mode — not the average smoker’s failure mode. You learned that the morning coffee trigger is your hardest. You learned that you can manage cravings until day 9 but not past day 14 without behavioral support. You learned that 21mg patches alone aren’t enough. None of this is in the literature; it’s in your specific history.

A new method erases this calibration. You’re back to baseline knowledge of your own response curve.

This argues for what most quit-smoking content does not argue for: trying the same method again, with explicit identification of what failed last time and a plan that addresses that specific failure. If your last cold-turkey attempt collapsed at week 3 because of a single recurring trigger, the answer probably isn’t switching to varenicline. It’s cold turkey + a specific plan for that trigger.

Practical decision: how to actually pick

If you’ve never quit before:

  1. Combination NRT (21mg patch + 4mg gum) + a tracking tool, plus one named accountability person. This is the empirically-supported default, has a clean side-effect profile, and is available without prescription in most markets.

If you’ve quit before: 2. Same method as last time, plus a written analysis of what specifically failed. The probability that switching methods solves your specific failure mode is lower than you’d think.

If you have depression or active anxiety: 3. Address that first or in parallel, ideally with a clinician. Treating it raises baseline success rates more than method selection does.

If you smoke 30+/day: 4. Don’t rely on single-form NRT. Combination NRT or varenicline, both with behavioral support.

If you’ve quit successfully for >1 year before but relapsed: 5. The maintenance failure pattern is different from the initial-quit failure pattern. Look at what was happening in your life when you relapsed, not what method you used to quit originally.